 Immuron Limited ASX: IMC; NASDAQ: IMRN, an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced that the cash payments of Board fees will be suspended and replaced with Immuron stock. As announced to the market on 25 March, 2020 the Board and Executive Management reported that significant cost reductions measures have been implemented to preserve the Companys cash position. As part of these measures, Immurons Board of Directors the Board have resolved, for the foreseeable future, to relinquish cash payments of fees and in lieu of same receive common stock in the Company. 